Drug Approval | April 14, 2025
Aurolife Pharma gets 11 observations from USFDA for Raleigh plant
The company does not expect this development to have any material impact on the current business operations
The company does not expect this development to have any material impact on the current business operations
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
The National IP Awards recognize outstanding contributions to India’s innovation economy through effective IP creation and commercialization
Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla
Padmanabhan brings over two decades of extensive experience in FMCG sector
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older
The product will be launched in Q1FY26
This registration authorizes Nureca Technologies to continue manufacturing and exporting asuite of medical devices to the United States
David joins HCTI with a distinguished career of over 22 years of corporate finance experience
The supply of these goods is set to commence within the first quarter of FY26
Subscribe To Our Newsletter & Stay Updated
